Chronic Total Occlusion PCI in Cancer Patients: National Trends and Periprocedural Risk Stratification.

Authors

Adrian Nubla, Hugo Lopez-Arevalo, Keerthana Manjunath, Bilal Bajwa, Marco Dispagna, Yousif Mohammed-Helo, Revati Varma

Published in

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions. Aug 12, 2026. Epub Aug 12, 2026.

Abstract

Outcomes of chronic total occlusion (CTO) PCI in patients with active malignancy remain poorly characterized. We examined cancer prevalence trends and in-hospital outcomes among cancer patients undergoing CTO PCI nationally.
We analyzed the National Inpatient Sample (2016-2022), identifying CTO PCI admissions using ICD-10-CM/PCS codes. Survey-weighted multivariable logistic regression and inverse probability of treatment weighting (IPTW) compared outcomes in cancer versus no-cancer patients. Myelosuppression was examined as a prespecified high-risk subgroup.
Among 214,365 weighted CTO PCI admissions, 4135 (1.9%) involved active cancer. Although absolute CTO PCI volume declined, the proportion of recipients with active cancer increased over the study period (survey-weighted odds ratio [OR]/year 1.065, 95% confidence interval [CI] 1.028-1.104, p = 0.0007). Despite higher unadjusted mortality (5.2% vs. 3.7%), cancer was not independently associated with higher in-hospital mortality after multivariable adjustment (adjusted OR [aOR] 0.91, 95% CI 0.63-1.32, p = 0.62) or IPTW (aOR 1.14, 95% CI 0.76-1.70, p = 0.54). In an exploratory subgroup, myelosuppression was associated with more than twofold higher mortality (aOR 2.59, 95% CI 1.07-6.29, p = 0.037); though this finding is hypothesis-generating given the small sample (n = 44).
Active malignancy was not independently associated with in-hospital mortality among patients selected for CTO PCI, though findings cannot establish broad procedural safety given the pre-selected cohort. Myelosuppression and elevated transfusion risk represent periprocedural considerations warranting prospective validation.

PMID:
42583729
Bibliographic data and abstract were imported from PubMed on 12 Aug 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.